Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
Standard
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. / van Bömmel, Florian; Man, de; Robert, A; Wedemeyer, Heiner; Deterding, Katja; Buggisch, Peter; Buggisch, Peter; Erhardt, Andreas; Hüppe, Dietrich; Stein, Kerstin; Trojan, Jörg; Sarrazin, Christoph; Böcher, Wulf O; Spengler, Ulrich; Wasmuth, Hermann E; Reinders, Jurrien G P; Möller, Bernd; Peter, Rhode; Feucht, Heinz-Hubert; Wiedenmann, Bertram; Berg, Thomas.
In: HEPATOLOGY, Vol. 51, No. 1, 1, 2010, p. 73-80.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
AU - van Bömmel, Florian
AU - Man, de
AU - Robert, A
AU - Wedemeyer, Heiner
AU - Deterding, Katja
AU - Buggisch, Peter
AU - Buggisch, Peter
AU - Erhardt, Andreas
AU - Hüppe, Dietrich
AU - Stein, Kerstin
AU - Trojan, Jörg
AU - Sarrazin, Christoph
AU - Böcher, Wulf O
AU - Spengler, Ulrich
AU - Wasmuth, Hermann E
AU - Reinders, Jurrien G P
AU - Möller, Bernd
AU - Peter, Rhode
AU - Feucht, Heinz-Hubert
AU - Wiedenmann, Bertram
AU - Berg, Thomas
PY - 2010
Y1 - 2010
N2 - Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log(10) copies/mL at the start and a minimum period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 +/- 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of either monotherapy with lamivudine (LAM; n = 18), adefovir (ADV; n = 8), and sequential LAM-ADV therapy (n = 73), or add-on combination therapy with both drugs (n = 29). Three patients had failed entecavir therapy. Resistance analysis in 113 of the 131 patients revealed genotypic LAM and ADV resistance in 62% and 19% of patients, respectively. The mean HBV DNA level at TDF baseline was 7.6 +/- 1.5 log(10) copies/mL. The overall cumulative proportion of patients achieving HBV DNA levels
AB - Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment-naive patients with chronic hepatitis B virus (HBV) infection but experience in nucleoside/nucleotide analogue (NA)-experienced patients is limited. In this retrospective multicenter study we therefore assessed the long-term efficacy of TDF monotherapy in patients with prior failure or resistance to different NA treatments. Criteria for inclusion were HBV DNA levels >4.0 log(10) copies/mL at the start and a minimum period of TDF therapy for at least 6 months. In all, 131 patients (mean age 42 +/- 12 years, 95 male, 65% hepatitis B e antigen [HBeAg]-positive) were eligible. Pretreatment consisted of either monotherapy with lamivudine (LAM; n = 18), adefovir (ADV; n = 8), and sequential LAM-ADV therapy (n = 73), or add-on combination therapy with both drugs (n = 29). Three patients had failed entecavir therapy. Resistance analysis in 113 of the 131 patients revealed genotypic LAM and ADV resistance in 62% and 19% of patients, respectively. The mean HBV DNA level at TDF baseline was 7.6 +/- 1.5 log(10) copies/mL. The overall cumulative proportion of patients achieving HBV DNA levels
M3 - SCORING: Zeitschriftenaufsatz
VL - 51
SP - 73
EP - 80
JO - HEPATOLOGY
JF - HEPATOLOGY
SN - 0270-9139
IS - 1
M1 - 1
ER -
